Holen Sie sich die Stockscreener-App
10.25
2.04%
0.1503
Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten
Securities Class Action Lawsuit Filed Against MoonLake Immunotherapeutics (MLTX)Levi & Korsinsky Represents Shareholders - The Globe and Mail
Lost Money on MoonLake Immunotherapeutics(MLTX)? Join Class Acti - GuruFocus
MLTX CLASS ACTION NOTICE: Berger Montague Encourages MoonLake Immunotherapeutics (NASDAQ - MarketScreener
MLTX INVESTOR CLASS ACTION: MoonLake Immunotherapeutics has - GlobeNewswire
H.C. Wainwright upgrades Moonlake stock rating to Buy with $30 price target - Investing.com
MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ... - Bluefield Daily Telegraph
MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) SHAREHOLDER - GlobeNewswire
2025-11-02 | Join Class Action to Recover Losses from MoonLake Immunotherapeutics (MLTX)Contact Levi & Korsinsky Before December 15, 2025 | NDAQ:MLTX | Press Release - Stockhouse
2025-11-02 | MLTX ALERT: Securities Fraud Class Action Launched Against MoonLake ImmunotherapeuticsDecember 15, 2025 Deadline | NDAQ:MLTX | Press Release - Stockhouse
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors to ... - Bluefield Daily Telegraph
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action – MLTX - GlobeNewswire Inc.
Can MoonLake Immunotherapeutics stock deliver sustainable ROEJuly 2025 Gainers & Verified Technical Signals - newser.com
MoonLake Immunotherapeutics Class Action: MLTX Stockholders Shou - GuruFocus
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading 6.7% HigherShould You Buy? - MarketBeat
MoonLake Immunotherapeutics Class Action: MLTX Stockholders Should Contact Robbins LLP for Information About the Class Action Against - PR Newswire
Levi & Korsinsky Notifies MoonLake Immunotherapeutics (MLTX) InvestorsLead Plaintiff Deadline on December 15, 2025 - Newsfile
MoonLake Immunotherapeutics Securities Fraud Class Action - GlobeNewswire
MLTX Investors Have Opportunity to Lead MoonLake - GlobeNewswire
MoonLake Immunotherapeutics (MLTX) Faces Securities Class - GlobeNewswire
DEADLINE ALERT for MLTX, BAX, and JHX: The Law Offices of - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - Newsfile
Visualizing MoonLake Immunotherapeutics stock with heatmapsJuly 2025 Update & Short-Term Trading Opportunity Alerts - newser.com
Can MoonLake Immunotherapeutics stock beat analyst upgradesJuly 2025 Pullbacks & Daily Stock Momentum Reports - newser.com
How MoonLake Immunotherapeutics stock trades during market volatilityQuarterly Trade Summary & Verified Entry Point Signals - newser.com
Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - Business Wire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Moonlake Immunotherapeutics, Inc. Investors - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in MoonLake Immunotherapeutics of Class Action Lawsuit and Upcoming DeadlinesMLTX - FinancialContent
MLTX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MoonLake Immunotherapeutics Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
MLTX INVESTOR ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate — Hagens Berman - Morningstar
The Gross Law Firm Notifies MoonLake Immunotherapeutics Investors of a Class Action Lawsuit and Upcoming DeadlineMLTX - MarketScreener
MoonLake Immunotherapeutics (MLTX) Projected to Post Earnings on Thursday - MarketBeat
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) - openPR.com
Deadline Approaching: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith - MarketScreener
Shareholders SueWallSt in New Class Action Against MoonLake ImmunotherapeuticsAct Now - Nasdaq
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - GlobeNewswire
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Citi - TipRanks
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
MLTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MoonLake Immunotherapeutics Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
MOONLAKE IMMUNOTHERAPEUTICS SECURITIES FRAUD NOTICE: Berger Montague Informs MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors of Securities Fraud Lawsuit - Your Wyoming Link
Is MoonLake Immunotherapeutics stock resilient to inflationWeekly Trading Summary & Reliable Breakout Stock Forecasts - Fundação Cultural do Pará
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit - Morningstar
MoonLake Immunotherapeutics Sued for Securities Law - GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure ... - Bluefield Daily Telegraph
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages MoonLake - GlobeNewswire
How supply chain issues affect MoonLake Immunotherapeutics stockWeekly Investment Report & Safe Capital Investment Plans - fcp.pa.gov.br
Law Offices of Frank R. Cruz Encourages MoonLake Immunotherapeutics (MLTX) Shareholders to Inquire About Securities Fraud Class Action - MarketScreener
Levi & Korsinsky Notifies Shareholders of MoonLake Immunotherapeutics (MLTX) of a Class Action Lawsuit and an Upcoming Deadline - NewMediaWire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims o - GuruFocus
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - MarketScreener
Oppenheimer Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX) - The Globe and Mail
Levi & Korsinsky Notifies Shareholders of MoonLake Immunotherapeutics(MLTX) of a Class Action Lawsuit and an Upcoming Deadline - MarketScreener
SHAREHOLDER ALERT: MoonLake Immunotherapeutics (NASDAQ:MLTX) Faces Securities Class Action after 90% Stock Drop; Contact BFA Law by December 15 Legal Deadline - GlobeNewswire
Will MoonLake Immunotherapeutics stock pay special dividendsEarnings Performance Report & Weekly Watchlist for Consistent Profits - fcp.pa.gov.br
Is MoonLake Immunotherapeutics stock positioned for digital transformationWeekly Trade Summary & Reliable Breakout Forecasts - fcp.pa.gov.br
SHAREHOLDER ALERT: DiCello Levitt LLP Announces That A - GlobeNewswire
Moonlake Immunotherapeutics Advances Psoriatic Arthritis Treatment with Sonelokimab Study - TipRanks
0.21%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):